NDA 020123 · Ge Healthcare
Omniscan
Gadodiamide · Injection · Paramagnetic Contrast Agent
NovelLast checked: Nov 19, 2026Latest source record: Mar 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Jan 8, 1993
Approved uses
4
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 1 recruiting
FAERS reports
3,361
3,114 serious, 374 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS See full prescribing information for complete boxed warning. Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. OMNISCAN is not approved for intrathecal use ( 5.1 ). GBCAs increase the risk for nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. Avoid use of OMNISCAN in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. Do not administer OMNISCAN to patients with: chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or acute kidney injury ( 4 ). Screen patients for acute kidney injury and other conditions that...
What it is approved for
From the label in effect Apr 18, 2025.
OMNISCAN is a gadolinium-based contrast agent for diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to: Visualize lesions with abnormal vascularity in the brain, spine, and associated tissues ( 1.1 ) Facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space ( 1.2 ) 1.1 CNS (Central Nervous System) OMNISCAN is a gadolinium-based contrast agent indicated for intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues [see Clinical Studies (14.1) ]. 1.2 Body (Intrathoracic [noncardiac], Intra-abdominal, Pelvic and Retroperitoneal Regions) OMNISCAN is a gadolinium-based contrast agent indicated for intravenous use in MRI to facilitate the visualization of lesions with abnormal vascularity within the thoracic (noncardiac), abdominal, pelvic cavities, and the retroperitoneal space [see Clinical Studies (14.2) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 5, 1996 Supplement 4 · Efficacy
- Feb 5, 1996 Supplement 7 · Efficacy
- Feb 5, 1996 Supplement 5 · Efficacy
- Jan 8, 1993 Original approval · Type 1 - New Molecular Entity Other Important Information from FDA
1 products under this application
- OMNISCAN · GADODIAMIDE 287MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadodiamide" as an intervention, any sponsor and status, largest first.
GuerbetIndustry
NCT04373564 · 2,076 participants (planned) · Start Mar 24, 2021 · Primary completion Dec 31, 2028
Drug: Gadoxetate disodium; Gadobenate dimeglumine and 4 more · For: Motor Function; Cognitive Function; Contrast Media
Sites: Scottsdale, Arizona; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance ImagingPivotal-lookingStatus unknown
The Central Hospital of Lishui CityAcademic, hospital or other
NCT04776187 · 600 participants (planned) · Start Mar 1, 2021 · Primary completion Dec 31, 2021
Drug: Gadodiamide; Gadoteric Acid Meglumine Salt · For: Nephrogenic Fibrosing Dermopathy
Sites: Lishui, China
- A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using GadodiamidePivotal-lookingCompleted
GE HealthcareIndustry
NCT00209443 · 407 participants · Start Sep 2004 · Primary completion Feb 28, 2006
Drug: Gadodiamide Injection · For: Aorto-iliac Stenosis; Arterial Occlusive Diseases
Sites: Ismaning, Germany
- A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using GadodiamidePivotal-lookingCompleted
GE HealthcareIndustry
NCT00209391 · 395 participants · Start Sep 2003 · Primary completion Aug 1, 2005
Drug: Gadodiamide Injection · For: Renal Artery Stenosis
Sites: Ismaning, Germany
GE HealthcareIndustry
NCT00908310 · 213 participants · Start May 2009 · Primary completion Jun 2013
Drug: Omniscan · For: Chronic Kidney Disease; Renal Insufficiency
Sites: Princeton, New Jersey
- A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the BrainPivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT00323102 · 114 participants · Start May 2006
Drug: Multihance · For: Brain Pathology
Sites: Princeton, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nephrogenic systemic fibrosis2,226
- pain758
- anxiety432
- emotional distress398
- injury397
- mobility decreased355
- arthralgia345
- skin hypertrophy275
- fibrosis273
- general physical health deterioration270
- skin induration266
- oedema peripheral264
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 12 |
| 2006 | 53 |
| 2007 | 246 |
| 2008 | 295 |
| 2009 | 258 |
| 2010 | 360 |
| 2011 | 351 |
| 2012 | 137 |
| 2013 | 115 |
| 2014 | 714 |
| 2015 | 94 |
| 2016 | 82 |
| 2017 | 101 |
| 2018 | 74 |
| 2019 | 204 |
| 2020 | 114 |
| 2021 | 31 |
| 2022 | 18 |
| 2023 | 24 |
| 2024 | 22 |
| 2025 | 17 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety of gadodiamide injection in two different age groups.
Högström B, Kristoffersen DT, Lundby B, et al. · J Magn Reson Imaging 1996 · Meta-Analysis
- Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system.
Ekholm S, Jonsson E, Sandvik L, et al. · Acta Radiol 1996 · Clinical Trial, Multicenter Study
- Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA.
Balériaux D, Matos C, De Greef D · Neuroradiology 1993 · Clinical Trial, Clinical Trial, Phase III
- Skull base tumors: gadodiamide injection--enhanced MR imaging--drop-out effect in the early enhancement pattern of paragangliomas versus different tumors.
Vogl TJ, Mack MG, Juergens M, et al. · Radiology 1993 · Clinical Trial, Clinical Trial, Phase III
- Effect of dose and field strength on enhancement with paramagnetic contrast media.
Lindsey RO, Yetkin FZ, Prost R, et al. · AJNR Am J Neuroradiol 1994 · Clinical Trial, Clinical Trial, Phase III
- Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
Van Wagoner M, Worah D · Invest Radiol 1993 · Clinical Trial, Clinical Trial, Phase I
Sponsor: Ge Healthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.